NeuroOne Medical Technologies Corporation NMTC
- Market cap
- $12.1M
- P/E
- 0.0×
Follow NMTC
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.90 | 9.90 | 54.00 | 21.78 | 14.94 | 11.22 | 3.06 | 5.10 | 3.31 | 2.37 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 9.90 | 76.50 | 180.00 | 178.02 | 46.80 | 81.00 | 19.08 | 13.08 | 10.07 | 8.34 |
High Price
|
|||
| — | — | — | — | — | 11 | 15 | 16 | 17 | 18 |
Employees
|
|||
| — | — | — | — | 0 | 0 | 0 | 0 | 0 | 1 |
Revenue/Emp
|
|||
| — | — | — | — | 2 | 0 | 2 | 3 | 3 | 12 |
Revenue
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | (13.54%) | 88.59% | 56.10% | 31.27% | 67.30% |
Gross Margin
|
|||
| 0 | (5) | (7) | (7) | (14) | (10) | (10) | (12) | (12) | (4) |
EBT
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | (707.99%) | (4,093.91%) | (471.68%) | (348.03%) | (356.74%) | (29.80%) |
EBT Margin
|
|||
| 0 | 0 | (7) | (7) | (14) | (10) | (10) | (12) | (12) | (4) |
Net Income
|
|||
| 0 | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 2.13 | 0.14 | 0.79 | 1.13 | 0.77 | 1.81 |
Revenue/Sh
|
|||
| (0.16) | (2.31) | (2.43) | (1.72) | (15.11) | (5.58) | (3.78) | (3.90) | (2.76) | (0.54) |
Earnings/Sh
|
|||
| (0.07) | (0.96) | 0.00 | (1.37) | (3.79) | (4.82) | (2.82) | (4.27) | (2.47) | (0.42) |
Cash Flow/Sh
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | (0.14) | (0.04) | (0.10) | (0.12) | (0.03) | (0.01) |
Capex/Sh
|
|||
| (0.07) | (0.96) | 0.00 | (1.37) | (3.93) | (4.86) | (2.92) | (4.39) | (2.50) | (0.44) |
Free CF/Sh
|
|||
| (0.11) | (2.29) | (1.57) | (0.31) | 2.29 | 3.68 | 3.60 | 2.07 | 0.18 | 1.06 |
Book Value/Sh
|
|||
| 2 | 2 | 3 | 4 | 1 | 2 | 3 | 3 | 4 | 7 |
Shares
|
|||
| — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | 0.00 | 173.99 | 12.76 | 4.95 | 7.67 | 2.95 |
PS Ratio
|
|||
| — | — | — | — | 82.77 | 6.45 | 2.82 | 2.70 | 32.24 | 5.04 |
PB Ratio
|
|||
| — | — | — | — | 0.00 | 145.58 | 7.50 | 3.38 | 7.25 | 2.41 |
EV/Sales
|
|||
| — | — | — | — | 0.00 | (4.11) | (2.04) | (0.87) | (2.25) | (9.97) |
EV/FCF
|
|||
| 0 | (2) | — | (5) | (3) | (9) | (8) | (13) | (11) | (3) |
Op' Cash Flow
|
|||
| — | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capex
|
|||
| 0 | (2) | — | (5) | (4) | (9) | (8) | (13) | (11) | (3) |
FCF
|
|||
| 0 | (4) | (4) | (1) | 2 | 6 | 9 | 6 | 2 | 8 |
Working Cap'
|
|||
| 0 | 2 | 2 | — | 1 | 0 | 0 | 0 | — | — |
Total Debt
|
|||
| 0 | 2 | 2 | 0 | (4) | (7) | (11) | (5) | (1) | (7) |
Net Debt
|
|||
| 0 | (5) | (4) | (1) | 2 | 7 | 10 | 6 | 1 | 7 |
Sh' Equity
|
|||
| (56.61%) | (1,336.61%) | (6,243.07%) | (1,805.19%) | (515.46%) | (156.69%) | (96.33%) | (113.38%) | (182.93%) | (44.63%) |
ROA
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (806.13%) | 0.00% | (526.10%) |
ROIC
|
|||
| 10.75% | 190.78% | 144.75% | 240.75% | (3,292.35%) | (230.81%) | (123.77%) | (149.61%) | (348.39%) | (91.34%) |
ROE
|
|||
NeuroOne Medical Technologies Corporation peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SINT SINTX TECHNOLOGIES, INC. | $12.5M | 0.0× | Compare |
| PETV PetVivo Holdings, Inc. | $12.9M | 0.0× | Compare |
| BMRA Biomerica, Inc. | $11.3M | 0.0× | Compare |
| IRIX IRIDEX Corporation | $11.1M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PMI Flag Ship Acquisition Corp | $11.1M | 0.2× | Compare |
| BTCY Biotricity Inc. | $10.9M | 0.0× | Compare |
| CTSO Cytosorbents Corporation | $13.6M | 0.0× | Compare |
| AEMD Aethlon Medical, Inc. | $10.4M | 0.0× | Compare |
NeuroOne Medical Technologies Corporation (NMTC) key facts
- NeuroOne Medical Technologies Corporation (NMTC) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- NeuroOne Medical Technologies Corporation’s revenue for fiscal 2025 (year ended September 2025) was $12.1 million, up 250.4% from fiscal 2024.
- As of September 25, 2026, NMTC traded at $1.33, a market capitalization of $12.1 million.
- Return on equity was −91.3% and debt-to-equity 0.00.
NeuroOne Medical Technologies Corporation (NMTC) Latest News
27 Aug
NeuroOne Medical Technologies Corporation achieved successful robotic-assisted drug delivery using its next-generation StereoCED platform. Successful StereoCED platform deployment advances core neurotechnology and strengthens competitive positioning.
20 Aug
NeuroOne (NMTC) held its Q3 2026 earnings call covering financial results and operational updates. Earnings call provides financial results and outlook that can shift near-term investor sentiment and valuation.
17 Aug
NeuroOne Medical Technologies Corp reported 16% revenue growth in Q3 2026 earnings call highlights. 16% quarterly revenue growth signals moderate financial progress for NeuroOne without major strategic or market-altering developments.
13 Aug
NeuroOne Medical Technologies Corporation reported Q3 2026 financial results during its earnings call, covering revenue, expenses, product progress, and forward outlook for its neurotechnology business. Earnings call details on results and guidance can shift near-term investor views and valuation without altering long-term company direction.
NeuroOne Medical Technologies Corporation reported fiscal Q3 2026 revenues of $2.0 million, a 16% year-over-year increase, with gross margins expanding to 59.9%. Revenue growth and margin expansion signal moderately noticeable improvement in financial performance.
11 Aug
NeuroOne Medical Technologies Corporation achieves ISO 13485 certification as a major milestone. ISO 13485 certification supports regulatory compliance and medical device commercialization.
30 Jul
NeuroOne Medical Technologies Corporation releases CNS drug delivery white paper ahead of planned fiscal year-end availability of the StereoCED platform. White paper and upcoming platform launch signal moderate product innovation progress without immediate major financial or market shifts.
28 Jul
NeuroOne highlights potential paradigm shift for patients treated with OneRF Brain Ablation System based on physician reports. Physician reports on OneRF system point to paradigm shift in brain ablation that could significantly boost NeuroOne market trajectory.
16 Jul
NeuroOne Medical Technologies Corporation collaborates on a pediatric brain cancer clinical trial to expand its drug delivery program. Collaboration advances NeuroOne into new pediatric clinical applications for its drug delivery technologies.
22 May
NeuroOne Medical Technologies Corporation announces restatement of financial results for quarter ending March 31, 2026. Financial restatement signals potential accounting issues that could influence market sentiment and short-term stock performance.
13 May
NeuroOne Medical Technologies Corporation held its Q2 2026 earnings call, covering financial results and business updates. Q2 earnings call reveals financial metrics that can influence short-term stock movement and operational insights.
12 May
NeuroOne Medical Technologies Corp (NMTC) Q2 2026 earnings call highlights strong product performance, revenue growth, and positive outlook. Strong Q2 2026 earnings highlights signal significant revenue growth and product momentum poised to enhance NMTC's market position and investor sentiment.
NeuroOne Medical Technologies Corporation reported fiscal Q2 2026 financial results and provided a corporate business update. Quarterly financial results and business update moderately affect financial performance and investor sentiment.
4 May
NeuroOne Medical Technologies Corporation (NMTC) has regained compliance with Nasdaq listing requirements after addressing prior deficiencies. Regaining Nasdaq compliance prevents delisting risk, ensuring continued trading access and enhancing investor confidence.
15 Apr
NeuroOne Medical Technologies Corporation advances its brain drug delivery platform through a collaboration with the University of Minnesota. University of Minnesota collaboration advances NMTC's brain drug delivery platform, enabling significant product innovation and competitive positioning.
14 Apr
NeuroOne Medical Technologies Corporation announced a reverse stock split to regain Nasdaq compliance by meeting the $1.00 minimum bid price requirement. Reverse stock split prevents delisting and maintains Nasdaq listing, significantly impacting market access and investor sentiment despite potential negative perception.
26 Mar
NeuroOne Medical Technologies Corporation successfully completed the limited market release of its OneRF Trigeminal Nerve Ablation System. Successful limited market release of OneRF Trigeminal Nerve Ablation System advances NMTC's product pipeline and commercialization efforts significantly.
17 Mar
NeuroOne Medical Technologies Corporation announced publication of clinical experience with its OneRF sEEG-guided radiofrequency ablation technology. Publication of clinical data validates OneRF technology, potentially accelerating adoption, partnerships, and investor confidence.
9 Mar
NeuroOne Medical Technologies Corporation issued a shareholder letter and provided a corporate update on operations, product developments, and strategic initiatives. Shareholder letter and corporate update highlight operational progress and future plans with moderate potential to affect financial performance and market sentiment.
3 Mar
NeuroOne Medical Technologies Corporation appointed David Wambeke as Chief Business Officer and concurrently completed an insider purchase of 1 million shares. Appointing a Chief Business Officer combined with a 1 million share insider purchase indicates major strategic leadership enhancement and strong internal confidence likely to boost investor sentiment and market performance.
17 Feb
NeuroOne Medical Technologies Corp (NMTC) Q1 2026 earnings call highlights navigating revenue challenges amid operational updates and future strategies. Q1 2026 earnings highlights outline revenue navigation strategies and financial performance updates significantly influencing NMTC's trajectory and market sentiment.
NeuroOne Medical Technologies reported fiscal Q1 2026 financial results and expects product revenue of at least $10.5 million in fiscal year 2026. Q1 2026 results and $10.5 million FY2026 revenue guidance indicate substantial growth, poised to boost investor sentiment and alter trajectory.
NeuroOne Medical Technologies Corporation (NMTC) Q1 2026 earnings call summary covers financial results, operational updates, and forward-looking guidance for the medical technology firm. Quarterly earnings summary reveals financial health and guidance impacting near-term market performance and investor sentiment.
6 Jan
NeuroOne Medical Technologies Corporation (NMTC) has been identified as a strong buy stock for January 6th, indicating positive market sentiment and potential growth opportunities for the company. The recommendation suggests that NMTC may be well-positioned for future performance, attracting investor interest. The strong buy recommendation indicates significant potential for future growth and positive market sentiment surrounding NMTC.
22 Dec
NeuroOne Medical Technologies Corporation has appointed Jason Mills to its Board of Directors. Mills brings extensive experience in the medical device industry, having held various leadership roles. His appointment is expected to enhance the company's strategic direction and governance as it continues to develop innovative technologies for neurological disorders. Mills' appointment may positively influence the company's strategic direction and governance, impacting its competitive positioning.
18 Dec
NeuroOne Medical Technologies Corporation (NMTC) reported record revenue in its Q4 2025 earnings call, highlighting significant growth and advancements in its product offerings. The company emphasized its commitment to innovation in neurotechnology and outlined strategic plans for future expansion. Key financial metrics showcased a strong performance, indicating positive market reception and potential for continued success in the industry. Record revenue and strategic plans indicate significant potential for future growth and market impact.
17 Dec
NeuroOne Medical Technologies Corporation (NMTC) reported a strong financial performance for the fourth quarter of fiscal 2025, with product revenue growth of 907% to $2.7 million and a gross margin of 55.8%. Total revenue for the fiscal year reached $9.1 million, reflecting a growth of 163%. The significant revenue growth and improved margins indicate a strong market position and potential for future expansion.
9 Dec
NeuroOne Medical Technologies Corporation announced the successful completion of initial cases using its OneRF Trigeminal Nerve Ablation System at University Hospitals in Cleveland. This marks a significant milestone in the company's efforts to advance its neuromodulation technologies for treating chronic pain conditions. Successful initial cases with a new medical device can significantly enhance market positioning and investor confidence.
19 Nov
NeuroOne Medical Technologies Corporation (NMTC) announced its participation in an upcoming industry conference, highlighting its commitment to advancing medical technology and engaging with industry leaders. The conference will provide a platform for NMTC to showcase its innovations and connect with potential partners and investors. Participation in industry conferences can enhance visibility and networking opportunities, potentially influencing market sentiment and product innovation.
6 Nov
NeuroOne Medical Technologies Corporation (NMTC) is under scrutiny regarding its cash management strategies. Investors are hopeful that the company will utilize its financial resources effectively to support growth and innovation in its medical technology offerings. The focus is on how NMTC plans to navigate its financial landscape amidst market challenges and competition in the healthcare sector. Effective cash management could moderately influence NMTC's financial performance and competitive positioning.